Literature DB >> 25372211

Retinal blood flow levels measured by laser speckle flowgraphy in patients who received intravitreal bevacizumab injection for macular edema secondary to central retinal vein occlusion.

Makiko Matsumoto1, Kiyoshi Suzuma, Yoshiko Fukazawa, Yoshihisa Yamada, Eiko Tsuiki, Azusa Fujikawa, Takashi Kitaoka.   

Abstract

PURPOSE: To report retinal blood flow levels measured by Laser speckle flowgraphy in three patients after they received an intravitreal bevacizumab injection (IVB) for macular edema secondary to central retinal vein occlusion (CRVO).
METHODS: Three patients (3 eyes) being treated with IVB (1.25 mg/0.05 mL) for secondary macular edema of CRVO were examined. Laser speckle flowgraphy analyses of the blood flow were based on the examinations of mean blur rate (MBR) at the major vessels of the optic disk. Central retinal thickness (CRT) was measured by optical coherence tomography using Macular Cube 512 × 128 scanning protocol.
RESULTS: After the first IVB, Case 1 exhibited an increase in MBR and decrease in CRT. After 4 months, an additional injection was required because of a subsequent MBR decrease and CRT increase, which led to an increase in MBR and decrease in CRT similar to that observed after the first treatment. Subsequently, blood flow has continued to improve without additional IVB. Macular edema recurrence in Case 2 led to 3 further IVBs over a 6-month period. Although increases in MBR and decreases in CRT were noted, MBR values tended to decline after each IVB. In Case 3, macular edema recurrence led to 5 additional IVBs being carried out within a 1-year period. Continuous MBR increases and CRT decreases were observed in the patient after each IVB. By measuring MBR using laser speckle flowgraphy, we may predict the prognosis of CRVO.
CONCLUSION: Mean blur rate increases after IVB were confirmed by laser speckle flowgraphy in three patients. Even though CRVO pathology backgrounds can vary, laser speckle flowgraphy may be useful in both determining the CRVO prognosis and in evaluating treatment efficacy.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25372211     DOI: 10.1097/ICB.0000000000000005

Source DB:  PubMed          Journal:  Retin Cases Brief Rep        ISSN: 1935-1089


  7 in total

1.  Intravitreal bevacizumab treatment reduces ocular blood flow in retinopathy of prematurity: a four-case report.

Authors:  Tadashi Matsumoto; Takashi Itokawa; Tomoaki Shiba; Masahiko Tomita; Kotaro Hine; Norio Mizukaki; Hitoshi Yoda; Yuichi Hori
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2018-07-06       Impact factor: 3.117

2.  RETINAL BLOOD FLOW AFTER INTRAVITREAL BEVACIZUMAB IS A PREDICTIVE FACTOR FOR OUTCOMES OF MACULAR EDEMA ASSOCIATED WITH CENTRAL RETINAL VEIN OCCLUSION.

Authors:  Makiko Matsumoto; Kiyoshi Suzuma; Yoshihisa Yamada; Eiko Tsuiki; Azusa Fujikawa; Takashi Kitaoka
Journal:  Retina       Date:  2018-02       Impact factor: 4.256

3.  Retinal Microvascular Resistance Estimated from Waveform Analysis Is Significantly Higher With a Threshold Value in Central Retinal Vein Occlusion.

Authors:  Makiko Matsumoto; Kiyoshi Suzuma; Fumito Akiyama; Kanako Yamada; Shiori Harada; Eiko Tsuiki; Takashi Kitaoka
Journal:  Transl Vis Sci Technol       Date:  2020-12-06       Impact factor: 3.283

4.  Retinal Vascular Resistance Significantly Correlates With Visual Acuity After 1 Year of Anti-VEGF Therapy in Central Retinal Vein Occlusion.

Authors:  Makiko Matsumoto; Kiyoshi Suzuma; Fumito Akiyama; Kanako Yamada; Shiori Harada; Eiko Tsuiki; Takashi Kitaoka
Journal:  Transl Vis Sci Technol       Date:  2021-09-01       Impact factor: 3.283

5.  Correlation between optic nerve head circulation and visual function before and after anti-VEGF therapy for central retinal vein occlusion: prospective, interventional case series.

Authors:  Daisuke Nagasato; Yoshinori Mitamura; Kentaro Semba; Kei Akaiwa; Toshihiko Nagasawa; Yuki Yoshizumi; Hitoshi Tabuchi; Yoshiaki Kiuchi
Journal:  BMC Ophthalmol       Date:  2016-04-05       Impact factor: 2.209

Review 6.  Mystery of Retinal Vein Occlusion: Vasoactivity of the Vein and Possible Involvement of Endothelin-1.

Authors:  Teruyo Kida
Journal:  Biomed Res Int       Date:  2017-08-20       Impact factor: 3.411

7.  Time Course in Ocular Blood Flow and Pulse Waveform in a Case of Ocular Ischemic Syndrome with Intraocular Pressure Fluctuation.

Authors:  Ryo Yamazaki; Ryuya Hashimoto; Hidetaka Masahara; Masashi Sakamoto; Takatoshi Maeno
Journal:  Vision (Basel)       Date:  2020-06-10
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.